• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血因子VIIIa和凝血因子VIII在磷脂囊泡上与凝血因子IXa的结合。

Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.

作者信息

Duffy E J, Parker E T, Mutucumarana V P, Johnson A E, Lollar P

机构信息

Department of Medicine, Emory University, Atlanta, Georgia 30322.

出版信息

J Biol Chem. 1992 Aug 25;267(24):17006-11.

PMID:1512239
Abstract

The activation of factor X by factor IXa (fIXa) in the presence of phosphatidylcholine-phosphatidylserine (PCPS) vesicles is markedly accelerated by thrombin-activated factor VIII (fVIIIa). The interaction between highly purified fVIIIa and fIXa in this complex was studied fluorometrically at 25 degrees C by using a derivative of D-phenylalanyl-prolyl-arginyl-fIXa which was modified at the active site with fluorescein-5-maleimide (Fl-M-FPR-fIXa). Titration of Fl-M-FPR-fIXa with fVIIIa at fixed PCPS resulted in a large, saturable increase in anisotropy (delta r = 0.09). The titration data were fit to a model assuming a reversible equilibrium between fVIIIa and fIXa, resulting in an apparent dissociation constant of 2 nM and a stoichiometry of 1 mol of fVIIIa/mol of Fl-M-FPR-fIXa. The initial velocity of factor X activation was measured under identical conditions except that active fIXa and factor X were included, which yielded binding parameters similar to those determined fluorometrically. Thus, the fluorescence method accurately reflects complex formation between fVIIIa and fIXa on the phospholipid surface, and the fVIIIa-fIXa interaction is not influenced by the presence of the substrate, factor X. Addition of fVIII to Fl-M-FPR-fIXa and PCPS produced a small, saturable increase in anisotropy (delta r = 0.03), followed by a larger increase (delta r = 0.07) upon addition of thrombin to activate fVIII. Thus, fVIII binds fIXa, but proteolytic modification of fVIII must occur before the complete fVIIIa-dependent structural change in the active site of fIXa, as reflected in the anisotropy change, occurs

摘要

在磷脂酰胆碱 - 磷脂酰丝氨酸(PCPS)囊泡存在的情况下,凝血酶激活的因子VIII(fVIIIa)可显著加速因子IXa(fIXa)对因子X的激活。在25℃下,通过使用在活性位点用荧光素 - 5 - 马来酰亚胺(Fl - M - FPR - fIXa)修饰的D - 苯丙氨酰 - 脯氨酰 - 精氨酰 - fIXa衍生物,以荧光法研究了该复合物中高度纯化的fVIIIa与fIXa之间的相互作用。在固定的PCPS条件下,用fVIIIa滴定Fl - M - FPR - fIXa导致各向异性大幅增加且呈饱和状态(Δr = 0.09)。滴定数据符合一个假设fVIIIa与fIXa之间存在可逆平衡的模型,得出表观解离常数为2 nM,化学计量比为1摩尔fVIIIa /摩尔Fl - M - FPR - fIXa。在相同条件下测量因子X激活的初始速度,但加入了活性fIXa和因子X,得到的结合参数与荧光法测定的参数相似。因此,荧光法准确反映了磷脂表面上fVIIIa与fIXa之间的复合物形成,并且fVIIIa - fIXa相互作用不受底物因子X存在的影响。向Fl - M - FPR - fIXa和PCPS中加入fVIII会使各向异性小幅增加且呈饱和状态(Δr = 0.03),随后加入凝血酶激活fVIII后各向异性会有更大增加(Δr = 0.07)。因此,fVIII与fIXa结合,但在fIXa活性位点发生完全依赖fVIIIa的结构变化(如各向异性变化所反映)之前,fVIII必须先进行蛋白水解修饰。

相似文献

1
Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.凝血因子VIIIa和凝血因子VIII在磷脂囊泡上与凝血因子IXa的结合。
J Biol Chem. 1992 Aug 25;267(24):17006-11.
2
The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study.因子IXa的活性位点位于膜表面上方较远位置,且其构象在与因子VIIIa结合后会发生改变。一项荧光研究。
J Biol Chem. 1992 Aug 25;267(24):17012-21.
3
Structural and functional characterization of platelet receptor-mediated factor VIII binding.血小板受体介导的因子VIII结合的结构与功能特征
J Biol Chem. 2000 Apr 28;275(17):13071-81. doi: 10.1074/jbc.275.17.13071.
4
Maturation of coagulation factor IX during Xase formation as deduced using factor VIII-derived peptides.根据VIII 因子衍生肽推断 Xase 形成过程中凝血因子 IX 的成熟。
FEBS Open Bio. 2019 Aug;9(8):1370-1378. doi: 10.1002/2211-5463.12653. Epub 2019 Jul 2.
5
Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding.凝血因子IXa中的钠离子位点:对催化作用及因子VIIIa结合的影响
J Mol Biol. 2005 Jul 1;350(1):78-91. doi: 10.1016/j.jmb.2005.04.052.
6
Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase.凝血因子 VIIIa 的 A2 及 A3-C1-C2 亚基对凝血因子 X 酶中凝血因子 IXa 亲和力的作用。
Biochemistry. 2004 May 4;43(17):5094-101. doi: 10.1021/bi036289p.
7
Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex.与血友病A相关的凝血因子VIIIa A2亚基558 - 565环中的突变会改变因子X酶复合物的催化活性。
Blood. 2002 Jul 15;100(2):501-8. doi: 10.1182/blood-2001-12-0361.
8
Inhibition of human factor VIIIa by anti-A2 subunit antibodies.抗A2亚基抗体对人凝血因子VIIIa的抑制作用。
J Clin Invest. 1994 Jun;93(6):2497-504. doi: 10.1172/JCI117259.
9
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.二硫键稳定的凝血因子VIIIa变体的内在稳定性和功能特性
J Thromb Haemost. 2006 Jun;4(6):1315-22. doi: 10.1111/j.1538-7836.2006.01951.x.
10
Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.凝血酶对因子VIII的激活增加了其与合成磷脂膜及活化血小板结合的亲和力。
J Biol Chem. 1998 Oct 23;273(43):27918-26. doi: 10.1074/jbc.273.43.27918.

引用本文的文献

1
The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential.FVIII 中的 Asp519Val/Glu665Val 和 Lys1813Ala 突变的组合显著增加了凝血潜能。
Blood Adv. 2024 Aug 13;8(15):3929-3940. doi: 10.1182/bloodadvances.2023012391.
2
Factor IXa variants resistant to plasma inhibitors enhance clot formation in vivo.因子 IXa 变异体对血浆抑制剂的耐药性增强了体内血栓的形成。
Blood. 2023 Apr 20;141(16):2022-2032. doi: 10.1182/blood.2022018083.
3
Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential.
因子 VIII 突变的赖氨酸 1813 至丙氨酸位于因子 IXa 结合区域内,增强了固有凝血潜能。
Blood Adv. 2023 Apr 25;7(8):1436-1445. doi: 10.1182/bloodadvances.2022008187.
4
Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex.外位点结合可提高固有 X 酶复合物激活凝血因子 X 的底物亲和力。
J Biol Chem. 2020 Nov 6;295(45):15198-15207. doi: 10.1074/jbc.RA120.015325. Epub 2020 Aug 28.
5
Dimeric Organization of Blood Coagulation Factor VIII bound to Lipid Nanotubes.与脂质纳米管结合的血液凝固因子VIII的二聚体结构
Sci Rep. 2015 Jun 17;5:11212. doi: 10.1038/srep11212.
6
Lipid nanotechnologies for structural studies of membrane-associated proteins.用于膜相关蛋白结构研究的脂质纳米技术。
Proteins. 2014 Nov;82(11):2902-9. doi: 10.1002/prot.24631. Epub 2014 Jul 3.
7
A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.A3 结构域 1803-1818 有助于激活的因子 VIII 的稳定性,并且包含一个与激活的因子 IX 结合的位点。
J Biol Chem. 2013 Sep 6;288(36):26105-26111. doi: 10.1074/jbc.M113.500884. Epub 2013 Jul 24.
8
Blood Clotting Factor VIII: From Evolution to Therapy.凝血因子 VIII:从进化到治疗。
Acta Naturae. 2013 Apr;5(2):19-39.
9
The transition of prothrombin to thrombin.凝血酶原向凝血酶的转化。
J Thromb Haemost. 2013 Jun;11 Suppl 1(0 1):265-76. doi: 10.1111/jth.12217.
10
Membrane protein TM segments are retained at the translocon during integration until the nascent chain cues FRET-detected release into bulk lipid.膜蛋白 TM 片段在整合过程中保留在转位复合物中,直到新生链发出进入体相脂质的 FRET 检测到的释放信号。
Mol Cell. 2012 Nov 9;48(3):398-408. doi: 10.1016/j.molcel.2012.08.023. Epub 2012 Sep 27.